# Structure-Aware Contrastive Learning with Fine-Grained Binding Representations for Drug Discovery

**Korean Title:** ì•½ë¬¼ ë°œê²¬ì„ ìœ„í•œ ì„¸ë°€í•œ ê²°í•© í‘œí˜„ì„ í™œìš©í•œ êµ¬ì¡° ì¸ì‹ ëŒ€ì¡° í•™ìŠµ

## ğŸ“‹ ë©”íƒ€ë°ì´í„°

**Links**: [[daily/2025-09-18|2025-09-18]] [[authors/Jing Lan|Jing Lan]] [[authors/Hexiao Ding|Hexiao Ding]] [[authors/Hongzhao Chen|Hongzhao Chen]] [[authors/Yufeng Jiang|Yufeng Jiang]] [[authors/Nga-Chun Ng|Nga-Chun Ng]] [[categories/cs.AI|cs.AI]]

## ğŸ·ï¸ ì¹´í…Œê³ ë¦¬í™”ëœ í‚¤ì›Œë“œ
**ğŸ”— Specific Connectable**: Attention Mechanism, Virtual Screening

## ğŸ”— ìœ ì‚¬í•œ ë…¼ë¬¸
- [[(P)rior(D)yna(F)low_ A Priori Dynamic Workflow Construction via Multi-Agent Collaboration_20250919|(P)rior(D)yna(F)low A Priori Dynamic Workflow Construction via Multi-Agent Collaboration]] (79.2% similar)
- [[Generative AI for Misalignment-Resistant Virtual Staining to Accelerate Histopathology Workflows_20250918|Generative AI for Misalignment-Resistant Virtual Staining to Accelerate Histopathology Workflows]] (78.6% similar)
- [[Decoupled Proxy Alignment_ Mitigating Language Prior Conflict for Multimodal Alignment in MLLM_20250919|Decoupled Proxy Alignment Mitigating Language Prior Conflict for Multimodal Alignment in MLLM]] (78.5% similar)
- [[Learning Discrete Abstractions for Visual Rearrangement Tasks Using Vision-Guided Graph Coloring_20250919|Learning Discrete Abstractions for Visual Rearrangement Tasks Using Vision-Guided Graph Coloring]] (78.3% similar)
- [[Ensemble of Pathology Foundation Models for MIDOG 2025 Track 2_ Atypical Mitosis Classification_20250919|Ensemble of Pathology Foundation Models for MIDOG 2025 Track 2 Atypical Mitosis Classification]] (78.2% similar)

## ğŸ“‹ ì €ì ì •ë³´

**Authors:** Jing Lan, Hexiao Ding, Hongzhao Chen, Yufeng Jiang, Nga-Chun Ng, Gwing Kei Yip, Gerald W. Y. Cheng, Yunlin Mao, Jing Cai, Liang-ting Lin, Jung Sun Yoo

## ğŸ“„ Abstract (ì›ë¬¸)

Accurate identification of drug-target interactions (DTI) remains a central
challenge in computational pharmacology, where sequence-based methods offer
scalability. This work introduces a sequence-based drug-target interaction
framework that integrates structural priors into protein representations while
maintaining high-throughput screening capability. Evaluated across multiple
benchmarks, the model achieves state-of-the-art performance on Human and
BioSNAP datasets and remains competitive on BindingDB. In virtual screening
tasks, it surpasses prior methods on LIT-PCBA, yielding substantial gains in
AUROC and BEDROC. Ablation studies confirm the critical role of learned
aggregation, bilinear attention, and contrastive alignment in enhancing
predictive robustness. Embedding visualizations reveal improved spatial
correspondence with known binding pockets and highlight interpretable attention
patterns over ligand-residue contacts. These results validate the framework's
utility for scalable and structure-aware DTI prediction.

## ğŸ” Abstract (í•œê¸€ ë²ˆì—­)

ì•½ë¬¼-í‘œì  ìƒí˜¸ì‘ìš©(DTI)ì˜ ì •í™•í•œ ì‹ë³„ì€ ê³„ì‚° ì•½ë¦¬í•™ì—ì„œ ì—¬ì „íˆ ì¤‘ì‹¬ì ì¸ ê³¼ì œì´ë©°, ì„œì—´ ê¸°ë°˜ ë°©ë²•ì€ í™•ì¥ì„±ì„ ì œê³µí•©ë‹ˆë‹¤. ë³¸ ì—°êµ¬ëŠ” ì„œì—´ ê¸°ë°˜ ì•½ë¬¼-í‘œì  ìƒí˜¸ì‘ìš© í”„ë ˆì„ì›Œí¬ë¥¼ ì†Œê°œí•˜ë©°, ì´ëŠ” ë‹¨ë°±ì§ˆ í‘œí˜„ì— êµ¬ì¡°ì  ì‚¬ì „ ì§€ì‹ì„ í†µí•©í•˜ë©´ì„œë„ ê³ ì²˜ë¦¬ëŸ‰ ìŠ¤í¬ë¦¬ë‹ ëŠ¥ë ¥ì„ ìœ ì§€í•©ë‹ˆë‹¤. ì—¬ëŸ¬ ë²¤ì¹˜ë§ˆí¬ë¥¼ í†µí•´ í‰ê°€ëœ ì´ ëª¨ë¸ì€ Human ë° BioSNAP ë°ì´í„°ì…‹ì—ì„œ ìµœì²¨ë‹¨ ì„±ëŠ¥ì„ ë‹¬ì„±í•˜ê³ , BindingDBì—ì„œë„ ê²½ìŸë ¥ì„ ìœ ì§€í•©ë‹ˆë‹¤. ê°€ìƒ ìŠ¤í¬ë¦¬ë‹ ì‘ì—…ì—ì„œ LIT-PCBAì— ëŒ€í•œ ì´ì „ ë°©ë²•ì„ ëŠ¥ê°€í•˜ë©°, AUROC ë° BEDROCì—ì„œ ìƒë‹¹í•œ í–¥ìƒì„ ì´ëŒì–´ëƒ…ë‹ˆë‹¤. ì†Œê±° ì—°êµ¬ëŠ” í•™ìŠµëœ ì§‘ê³„, ì´ì¤‘ì„ í˜• ì£¼ì˜, ëŒ€ì¡°ì  ì •ë ¬ì´ ì˜ˆì¸¡ì˜ ê²¬ê³ ì„±ì„ í–¥ìƒì‹œí‚¤ëŠ” ë° ì¤‘ìš”í•œ ì—­í• ì„ í•œë‹¤ëŠ” ê²ƒì„ í™•ì¸í•©ë‹ˆë‹¤. ì„ë² ë”© ì‹œê°í™”ëŠ” ì•Œë ¤ì§„ ê²°í•© í¬ì¼“ê³¼ì˜ ê³µê°„ì  ëŒ€ì‘ì´ ê°œì„ ë˜ì—ˆìŒì„ ë³´ì—¬ì£¼ê³ , ë¦¬ê°„ë“œ-ì”ê¸° ì ‘ì´‰ì— ëŒ€í•œ í•´ì„ ê°€ëŠ¥í•œ ì£¼ì˜ íŒ¨í„´ì„ ê°•ì¡°í•©ë‹ˆë‹¤. ì´ëŸ¬í•œ ê²°ê³¼ëŠ” í™•ì¥ ê°€ëŠ¥í•˜ê³  êµ¬ì¡°ë¥¼ ì¸ì‹í•˜ëŠ” DTI ì˜ˆì¸¡ì„ ìœ„í•œ í”„ë ˆì„ì›Œí¬ì˜ ìœ ìš©ì„±ì„ ê²€ì¦í•©ë‹ˆë‹¤.

## ğŸ“ ìš”ì•½

ì´ ì—°êµ¬ëŠ” ì•½ë¬¼-í‘œì  ìƒí˜¸ì‘ìš©(DTI)ì˜ ì •í™•í•œ ì‹ë³„ì„ ìœ„í•œ ì‹œí€€ìŠ¤ ê¸°ë°˜ í”„ë ˆì„ì›Œí¬ë¥¼ ì œì•ˆí•˜ë©°, ë‹¨ë°±ì§ˆ í‘œí˜„ì— êµ¬ì¡°ì  ì‚¬ì „ ì§€ì‹ì„ í†µí•©í•˜ì—¬ ëŒ€ëŸ‰ ìŠ¤í¬ë¦¬ë‹ ê¸°ëŠ¥ì„ ìœ ì§€í•©ë‹ˆë‹¤. Human ë° BioSNAP ë°ì´í„°ì…‹ì—ì„œ ìµœì²¨ë‹¨ ì„±ëŠ¥ì„ ë³´ì˜€ìœ¼ë©°, BindingDBì—ì„œë„ ê²½ìŸë ¥ì„ ìœ ì§€í•©ë‹ˆë‹¤. ê°€ìƒ ìŠ¤í¬ë¦¬ë‹ ì‘ì—…ì—ì„œëŠ” LIT-PCBAì—ì„œ ì´ì „ ë°©ë²•ì„ ëŠ¥ê°€í•˜ì—¬ AUROCì™€ BEDROCì—ì„œ ìƒë‹¹í•œ í–¥ìƒì„ ë³´ì˜€ìŠµë‹ˆë‹¤. ì†Œê±° ì—°êµ¬ëŠ” í•™ìŠµëœ ì§‘ê³„, ì´ì¤‘ì„ í˜• ì£¼ì˜, ëŒ€ì¡° ì •ë ¬ì´ ì˜ˆì¸¡ ê°•ê±´ì„±ì„ ë†’ì´ëŠ” ë° ì¤‘ìš”í•¨ì„ í™•ì¸í–ˆìŠµë‹ˆë‹¤. ì„ë² ë”© ì‹œê°í™”ëŠ” ì•Œë ¤ì§„ ê²°í•© í¬ì¼“ê³¼ì˜ ê³µê°„ì  ëŒ€ì‘ì„ ê°œì„ í•˜ê³  ë¦¬ê°„ë“œ-ì”ê¸° ì ‘ì´‰ì— ëŒ€í•œ í•´ì„ ê°€ëŠ¥í•œ ì£¼ì˜ íŒ¨í„´ì„ ê°•ì¡°í•©ë‹ˆë‹¤. ì´ ê²°ê³¼ëŠ” í™•ì¥ ê°€ëŠ¥í•˜ê³  êµ¬ì¡°ë¥¼ ê³ ë ¤í•œ DTI ì˜ˆì¸¡ì— ëŒ€í•œ í”„ë ˆì„ì›Œí¬ì˜ ìœ ìš©ì„±ì„ ì…ì¦í•©ë‹ˆë‹¤.

## ğŸ¯ ì£¼ìš” í¬ì¸íŠ¸

- 1. ë³¸ ì—°êµ¬ëŠ” êµ¬ì¡°ì  ì •ë³´ë¥¼ í†µí•©í•œ ì„œì—´ ê¸°ë°˜ ì•½ë¬¼-í‘œì  ìƒí˜¸ì‘ìš© í”„ë ˆì„ì›Œí¬ë¥¼ ì œì•ˆí•˜ì—¬ ë†’ì€ ì²˜ë¦¬ëŸ‰ì˜ ìŠ¤í¬ë¦¬ë‹ ê¸°ëŠ¥ì„ ìœ ì§€í•©ë‹ˆë‹¤.

- 2. ì œì•ˆëœ ëª¨ë¸ì€ Human ë° BioSNAP ë°ì´í„°ì…‹ì—ì„œ ìµœì²¨ë‹¨ ì„±ëŠ¥ì„ ë‹¬ì„±í•˜ê³ , BindingDBì—ì„œë„ ê²½ìŸë ¥ì„ ìœ ì§€í•©ë‹ˆë‹¤.

- 3. ê°€ìƒ ìŠ¤í¬ë¦¬ë‹ ì‘ì—…ì—ì„œ LIT-PCBA ë°ì´í„°ì…‹ì— ëŒ€í•´ ì´ì „ ë°©ë²•ë“¤ì„ ëŠ¥ê°€í•˜ë©° AUROC ë° BEDROCì—ì„œ ìƒë‹¹í•œ í–¥ìƒì„ ë³´ì…ë‹ˆë‹¤.

- 4. ì†Œê±° ì—°êµ¬ëŠ” í•™ìŠµëœ ì§‘ê³„, ì´ì¤‘ ì„ í˜• ì£¼ì˜ ë©”ì»¤ë‹ˆì¦˜, ëŒ€ì¡° ì •ë ¬ì´ ì˜ˆì¸¡ì˜ ê²¬ê³ ì„±ì„ í–¥ìƒì‹œí‚¤ëŠ” ë° ì¤‘ìš”í•œ ì—­í• ì„ í•œë‹¤ëŠ” ê²ƒì„ í™•ì¸í•©ë‹ˆë‹¤.

- 5. ì„ë² ë”© ì‹œê°í™”ëŠ” ì•Œë ¤ì§„ ê²°í•© í¬ì¼“ê³¼ì˜ ê³µê°„ì  ëŒ€ì‘ì„ ê°œì„ í•˜ê³  ë¦¬ê°„ë“œ-ì”ê¸° ì ‘ì´‰ì— ëŒ€í•œ í•´ì„ ê°€ëŠ¥í•œ ì£¼ì˜ íŒ¨í„´ì„ ê°•ì¡°í•©ë‹ˆë‹¤.

---

*Generated on 2025-09-20 02:50:24*